new oral glp 1 agonist GLP-1 receptor agonists are generating a great deal of excitement as a potential inflection point in diabetes and obesity care. Amid the enthusiasm, however, a quieter and clinically important issue is Frontiers | Glucagon-like peptide-1 receptor

Sounds too good to be true, right

The truth is, glowing skin doesnt start on your face it starts inside your body

Heres the research physicians should know: Liew et al., 2014 (JAMA Pediatrics) risk ADHD/hyperkinetic disorders Brandlistuen et al., 2013 (IJE, MoBa Norway) Long-term use psychomotor & behavioral problems Avella-Garca et al., 2016 (IJE, Spain) ASD symptoms in boys, attention issues in both sexes Bornehag et al., 2018 (EHP, Sweden) Language delay in girls Ji et al., 2019 (JAMA Psychiatry) Cord blood biomarkers dose-response risk for ADHD & ASD Baker et al., 2020 (JAMA Pediatrics) Meconium biomarkers ADHD risk & altered brain connectivity Sznajder et al., 2022 (PLOS One) Use linked with neurobehavioral problems at 3 years Woodbury et al., 2024 (Pediatric Research / JDBP) Dose-response

10.1126/science.1191132 Science 119 MaughanS